Drugs in early clinical development for the treatment of female sexual dysfunction

@article{Belkin2015DrugsIE,
  title={Drugs in early clinical development for the treatment of female sexual dysfunction},
  author={Zoe R. Belkin and Jill M Krapf and Andrew T Goldstein},
  journal={Expert Opinion on Investigational Drugs},
  year={2015},
  volume={24},
  pages={159 - 167}
}
Introduction: There is growing recognition of female sexual dysfunction (FSD) as an important women’s health concern. Despite an increased awareness of the pathophysiologic components to FSD, currently, there are no drugs approved for the most common sexual complaint in women–decreased sexual desire. In response to an overwhelming demand for therapy for FSD, several drugs are undergoing development and testing. Areas covered: The aim of this paper is to provide the latest data on… 
Advances in pharmacotherapy for treating female sexual dysfunction
TLDR
The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model and discusses the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.
Pharmacotherapy for female sexual dysfunctions (FSDs): What is on the market and where is this field heading?
TLDR
The authors report the most recent advances in pharmacotherapy for premenopausal and postmenopausal women with a main focus on hypoactive sexual desire disorders (HSDD) and associated sexual symptoms.
Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women.
  • C. Borghi, L. Dell’Atti
  • Psychology, Medicine
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • 2017
TLDR
What is already known about the use of these vasoactive agents, particularly tadalafil, as a treatment option for female sexual disturbances is reviewed and phosphodiesterase type 5 inhibitors could be an effective option for many subtypes of female sexual disorders.
Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14.
The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder
TLDR
Evolving treatment strategies have relied heavily on these crucial research findings, as many of the agents currently being investigated as treatment options for HSDD target and influence key players within these excitatory and inhibitory pathways, including various hormone therapies and centrally acting drugs.
Future Targets for Female Sexual Dysfunction.
Future Directions in Sexual Medicine
TLDR
The pharmacological approach continues to be a mainstay of therapy, but an increased focus on psychosocial and lifestyle factors is beginning to play a pivotal role in creating a more balanced approach to the treatment of sexual dysfunction.
Evaluation and Treatment of Sexual Disorders Due to Medical Conditions
TLDR
This chapter discusses epidemiology, etiology, pathophysiology, diagnostic criteria, and best evidence-based practice and approaches to the diagnosis of sexual disorders due to medical conditions, and provides a review of diagnostic tests frequently used by physicians to aid in diagnosis and monitoring of treatment outcomes for sexual disorders.
...
1
2
3
...

References

SHOWING 1-10 OF 54 REFERENCES
Two novel combined drug treatments for women with hypoactive sexual desire disorder
Novel approaches to female sexual dysfunction
TLDR
The ideal approach to female sexual dysfunction is thus a collaborative effort between therapists and physicians, which should include a complete medical and psychosocial evaluation, as well as inclusion of the partner or spouse in the evaluation and treatment process.
Hypoactive sexual desire in women
TLDR
Low sexual desire is the most prevalent sexual problem in women and should be assessed and treated by healthcare professionals, and there are only modest evidence-based nonpharmacologic treatment options and no approved pharmacologic options.
Female sexual arousal disorders.
TLDR
Definitions of the different types of FSAD are given, their aetiology, prevalence and comorbidity with somatic and psychological disorders, as well as to discuss different medical and psychological assessment and treatment modalities are given.
Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues.
TLDR
It is demonstrated that on-demand T+PDE5i is a potentially promising treatment for women with HSDD, particularly in women with low sensitivity for sexual cues.
Toward personalized sexual medicine (part 1): integrating the "dual control model" into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder.
TLDR
It is hypothesized that a single dose of 5-hydroxytryptamine receptor agonist (5-HT(1A)ra) will reduce the sexual-stimulation-induced PFC-mediated sexual inhibition during a short period after administration, and treatment with T+5- HT(1 a)ra will be more effective, in particular in women exhibiting sexual inhibition.
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women
TLDR
By a local action in the vagina, DHEA applied daily at doses at which serum steroids remain well within normal postmenopausal values exerts relatively potent beneficial effects on all four aspects of sexual dysfunction.
DHEA for postmenopausal women: a review of the evidence.
Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS)
TLDR
HSDD is prevalent among women at all reproductive stages, with younger surgically postmenopausal women at greater risk, and is associated with a less active sex life and decreased sexual and relationship satisfaction.
A double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine.
TLDR
APO seemed to produce more subjective and objective changes in the sexual arousal phase of women with orgasmic sexual dysfunction than placebo, and future research is needed to evaluate the place of this drug in the treatment of the female sexual dysfunction.
...
1
2
3
4
5
...